Member Info for Threeskins

I sold a fairly substantial amount yesterday that took a while to clear, I felt I was massively over exposed on this stock. I may have been too impulsive and I've sold far to soon or good timing who knows, I will take it either way. I still hold a decent amount and believe in the company, I really want it to do well, but I am concerned as to why it is out of favour esp in the Covid world where we really are not being recognised at all. I do think that soon the PCR test will be redundant when the antigen test teething problems are sorted, I just hope that we have made hay while we can.
I also dont believe that the relatively low volume sell trades are holding the share price back, that is wishful thinking IMO, the market is always in the know before the punters and if there was a sniff the SP would start ticking.

bakky it was a sell.

Twix, my order took nearly 2hrs to clear this morning I guess not enough buyers for the sells.

It feels a bit like ground hog day again...next RNS is the big one blah blah blah. I really hope so, my fear is that pretty soon the rapid antigen test will super cede the PCR test and that vein of profitability will closed before its even started.

ColSoul I could do with a pint and I'd like to think something positive in the share price was going to happen next week. However from experience the punters are always last to know and if the market thought that something was on the cards the share price would be ticking a bit already. Sadly its not.

Considering the **** storm that we are in, especially in the NW, I will be very disappointed if YGEN aren't making good money of this.

possibly its likely to be on a sliding scale.

Caxton charging 19K for 200 test/wk.

NIPT contract RNS.

who?

How can Directors be buying now when we are so close to the half year results. Surely its a closed period for them?]

I see Genedrives Covid Kit got approval for South Africa.
On the subject of Genomics, personalized medicine has been the buzz word in Pharma for years and most companies are active in this field, whether it be looking for disease signatures and new drug targets or biomarker for tox, drug efficacy, target engagement. However there is big difference between de-convoluting the whole genome for this purpose and for designing companion diagnostic tests for mutations. The former is hugely big data based and require tremendous bioinformatics support. I dont know if YGEN are planning on going down this road or instead they tap into the findings from these efforts.

good to read they we are also using the gold standard sample collection tubes and some indication of where we have been targeting. Through my own role I am very familiar and have worked with Source BioScience and if we can emulate them I am a happy bunny and feeling very positive.

honestly , if in the next set of results we arent making decent money from this whole ****t stor/ Covid debacle, I will be seriously hacked off.

Interesting RNS, I just might check out and see what their genomic services arm is offering the next time I am looking for a CRO.

being Manchester based, I wonder if they have tapped into and capitalised on the testing requirements for all the pro football/sports teams in the NW area. They certainly have the money and each player/staff member needs to be tested every 5 days.

two big delayed sales for over a million shares?

did anyone ask what there thoughts are on as to why the SP seems locked in a
tight range despite 6 months of positive news and growth? It must be frustrating for them as well. What is the market cap requirement for NasDaq listing?

I've slightly mixed feelings about the statement. Whilst agreeing it is positive all round, I am slightly disappointed in the Covid screening numbers, ' building up to 10K a month' does not sound great to me especially given the competition in this climate for Covid screening . I think it says more about the 'true' capacity of YGEN despite the 'spin' (questionable) which course they have to do. I work in mid size BioPharma and personally use many CROs for routine screening esp PCR/RNASeq often when you look more closely at these outfits they struggle to meet numbers. Having said that I think YGEN is a sound business my main concern for this company is how they move forward with technology (they are heavily PCR based).

up 0.5p